Siegfried signs comprehensive cooperation agreement with Arena Pharmaceuticals

20-Dec-2007 - Siegfried has signed long-term cooperation agreements with Arena Pharmaceuticals, Inc. Under the agreement, primarily the active pharmaceutical ingredient (API) for Arena's drug Lorcaserin hydrochloride and other APIs will be produced at the Siegfried plant in Zofingen. For the production of its ...

Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial

13-Sep-2007 - Arena Pharmaceuticals, Inc. announced that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop the ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management). The BLOOM trial is ...

Arena Pharmaceuticals Announces Update on Partnership With Merck in Development of Niacin Receptor Agonists

28-Sep-2006 - Arena Pharmaceuticals, Inc. announced that an investigational niacin receptor agonist that was being developed under its partnership with Merck & Co., Inc. to develop drugs for the treatment of atherosclerosis and other disorders is no longer in development for the treatment of ...

Arena Pharmaceuticals Announces Achievement of Phase 2 Clinical Milestone Under Cardiovascular Disease Collaboration With Merck

22-May-2006 - Arena Pharmaceuticals, Inc. announced the initiation of a Phase 2 clinical trial of MK-0354, an Arena discovered orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. The Phase 2 clinical trial triggers a $4 million milestone ...

Arena Pharmaceuticals Issued Patent for 5-HT2A Receptor Modulators by European Patent Office

APD125, Arena's Drug Candidate for the Treatment of Insomnia, Covered Under Patent

02-Jan-2006 - Arena Pharmaceuticals, Inc. announced that it was granted patent number 1558582, entitled "Diaryl and Arylheteroaryl Urea Derivatives as Modulators of the 5-HT2A Serotonin Receptor Useful for the Prophylaxis and Treatment of Disorders Related Thereto," by the European Patent Office. The patent ...

Arena Pharmaceuticals' APD356 Selected as Winner of CONNECT's Most Innovative New Product Award in the Biotech R&D Category

14-Dec-2005 - Arena Pharmaceuticals, Inc. announced that their lead compound for the treatment of obesity, APD356, won San Diego based CONNECT's Most Innovative New Product ("MIP") Award in the Biotechnology Research and Development category. APD356 is a selective agonist of 5-HT2C serotonin receptors, which ...

Arena Pharmaceuticals Granted Patent for Drug Screening Methods Related to Ortho McNeil, Inc. Collaboration

15-Aug-2005 - Arena Pharmaceuticals, Inc. announced that it was granted patent number 1133559, entitled "HUMAN ORPHAN G PROTEIN-COUPLED RECEPTOR RUP3," by the European Patent Office. The patent relates to certain drug screening methods utilizing the 19AJ receptor, an orphan G protein-coupled receptor, or GPCR, ...

Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Novel Anti-Obesity Compound

12-May-2005 - Arena Pharmaceuticals, Inc. announced positive top-line results from its Phase 2 clinical trial of APD356, Arena's orally administered, internally discovered drug candidate for the treatment of obesity. Over the 28 day treatment period, there was a highly statistically significant (p=.0002) ...

Arena Pharmaceuticals Announces Achievement of a $3 Million Milestone Under Merck Collaboration for Assay Development

11-Aug-2004 - San Diego. Arena Pharmaceuticals, Inc. announced the achievement of a $3 million milestone from Merck & Co., Inc. for assay development under their cardiovascular collaboration. In 2002, Arena and Merck entered into a collaboration focused on a group of GPCR targets discovered by Arena, which ...